Hu Honglin, Xu Min, Qi Renjuan, Wang Youmin, Wang Changjiang, Liu Jiongjiong, Luo Li, Xia Li, Fang Zhaohui
Department of Endocrinology, The First Hospital of An Hui Medical University 218 Jixi Road, Hefei 230022, China.
Department of Endocrinology, The First Hospital of An Hui University of Chinese Medicine China.
Int J Clin Exp Med. 2015 Oct 15;8(10):17902-11. eCollection 2015.
The present study was designed to investigate the effects of sitagliptin on metabolic parameters as well as the expression levels of retinol-binding protein 4 (RBP4) and glucose transporter type 4 (GLUT4) in a rat model of type 2 diabetes mellitus. A rat model of type 2 diabetes mellitus was established by a combination of a high-fat diet and intraperitoneal injection of low-dose streptozotocin. Rats were divided into three groups: normal control group, diabetes group, and diabetes + sitagliptin group. Body weight, glycemic parameters, lipid profiles, fasting insulin (FINS) and serum RBP4 levels were assessed at baseline and after 6 weeks of therapy. Western blotting was used to detect the tissue RBP4 and GLUT4 expression levels. After treatment for 6 weeks, the diabetes + sitagliptin group displayed significantly improve levels of blood sugar, blood grease, and insulin sensitizing functions (P < 0.05) than the diabetes group. Sitagliptin markedly down regulated RBP4 expression levels and up-regulated GLUT4 expression levels in adipose tissue and skeletal muscle. The results indicate that sitagliptin can modulate the RBP4-GLUT4 system in adipose tissue and skeletal muscle. Modulation of the RBP4-GLUT4 system may be one of the mechanisms by which sitagliptin ameliorates the symptoms of type 2 diabetes mellitus.
本研究旨在探讨西他列汀对2型糖尿病大鼠模型代谢参数以及视黄醇结合蛋白4(RBP4)和葡萄糖转运蛋白4(GLUT4)表达水平的影响。通过高脂饮食和腹腔注射低剂量链脲佐菌素相结合的方法建立2型糖尿病大鼠模型。将大鼠分为三组:正常对照组、糖尿病组和糖尿病+西他列汀组。在基线和治疗6周后评估体重、血糖参数、血脂谱、空腹胰岛素(FINS)和血清RBP4水平。采用蛋白质免疫印迹法检测组织中RBP4和GLUT4的表达水平。治疗6周后,糖尿病+西他列汀组的血糖、血脂水平及胰岛素敏感功能较糖尿病组有显著改善(P<0.05)。西他列汀显著下调脂肪组织和骨骼肌中RBP4的表达水平,上调GLUT4的表达水平。结果表明,西他列汀可调节脂肪组织和骨骼肌中的RBP4 - GLUT4系统。RBP4 - GLUT4系统的调节可能是西他列汀改善2型糖尿病症状的机制之一。